New onset of uveitis during infliximab treatment: A case report


Mejda Bouladi
Amal Ben Othmen
Saoussen Miladi
Merieme Kalou
Ahmed Laatar
Lamia El Fekih


Introduction: Anti-tumor necrosis factor α (anti-TNF α) agents are an effective treatment for a variety of inflammatory and autoimmune diseases. In ophthalmology anti-TNF α began to emerge as a possible therapy for non-infectious uveitis, paradoxically their administration may result in the onset or recurrence of inflammatory eye disease such as uveitis.  We reported a case of new onset of bilateral anterior and intermediate uveitis in a patient with rheumatoid arthritis (RA) while being treated with infliximab and we performed a review of literature.

Observation : A 25-year-old female with RA under infliximab, presented with bilateral blurred vision. Anterior segment examination demonstrated retrodescmetic fine precipates, 1+ cells in the anterior chamber on both eyes. The fundus examination was difficult because of the vitritis. Fluorescein angiography demonstrated mild optic disc edema, and bilateral diffuse peripheral fern leaf cappilaritis. Optical coherence tomography showed severe cystoid macular edema bilaterally. The diagnosis of bilateral anterior and intermediate uveitis caused by infliximab was retained after exclusion of infectious and autoimmune aetiologies. She was treated with corticosteroid with good visual outcome.

Conclusion : In our case, new onset of uveitis may be considered as paradoxical effect of anti-TNF α therapy. Rheumatologists and ophthalmologists should be aware of this effect. Careful monitoring of patients under infliximab is necessary for appropriate diagnosis and early treatment.


case report, paradoxical effects, tumor necrosis factor-alpha



  1. - Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect 2020, 10(1).
  2. - Mahfoudhi M, Hariz A, Ben Abdelghani K, Turki S, Kheder A. Behcet's refractory uveitis treated successfully by infliximab. Tunis Med. 2014;92(1):41-2.
  3. - Cobo-Ibanez T, del Carmen Ordonez M, Munoz-Fernandez S, Madero-Prado R, Martin-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology 2008, 47(5), 731–732.
  4. - Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016, 2(2), e000239.
  5. - Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56(10), 3248–3252.
  6. - Iwahashi C, Ono H, Haruta M, Minami T, Mashimo H, Shimojo H, et al. New onset or exacerbation of uveitis with infliximab: paradoxical effects? BMJ Open Ophthalmology 2019;4:e000250.
  7. - Singla MB, Hodge DK, Moawad FJ. Infliximab-induced Anterior Uveitis in a Patient with Ulcerative Colitis. J Crohns Colitis 2015, 9(5), 432–432.
  8. - Ben Abdelghani K, Slouma M, Ben Jalel W, Zakraoui L. Retinal vasculitis: a novel paradoxical effect of anti-TNFα? BMJ Case Rep 2014. doi:10.1136/bcr-2014-204909.
  9. - Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008, 67(5), 729–730.